WHO ICTRP trial
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Adult Patients with…
NL-OMON34263 · Overview of Medical Research in the Netherlands (NL-OMON)
Key facts
| Trial ID | NL-OMON34263 |
|---|---|
| Public title | An Open-Label, Multi-Center Clinical Trial of Eculizumab in Adult Patients with Atypical Hemolytic-Uremic Syndrome |
| Scientific title | An Open-Label, Multi-Center Clinical Trial of Eculizumab in Adult Patients with Atypical Hemolytic-Uremic Syndrome - C10-004 |
| Primary sponsor | Alexion Pharmaceuticals |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Study type | Interventional |
| Phase | 2 |
| Countries | Belgium;Canada;France;Germany;Italy;Netherlands ;Spain;Switzerland;United Kingdom;United States of America |
| Conditions | atypical hemolytic-uremic syndrome;10018911;10027665;10029149;atypical hemolytic-uremic syndrome |
| Interventions | Eculizumab 600 mg, 900 mg or 1200 mg will be administered intravenously. ;Atypical Hemolytic-Uremic Syndrome;Eculizumab |
| Registration date | Mar 7, 2011 |
| Target size | 8 |
| Secondary IDs | 2010-020326-18;NCT01194973;NL33539.058.10 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: